{"entity":{"id":"nct06456463","kind":"trial","name":"A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy","aka":["TRILLIUM"],"tldr":"A phase 2 trial of Tagraxofusp, Venetoclax and Azacitidine in acute myeloid leukaemia, run by Stemline Therapeutics, Inc., active and no longer recruiting.","summary":"A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy is a phase 2 interventional study registered as NCT06456463 by Stemline Therapeutics, Inc., with 85 participants enrolled, started 2025-01-14 and due to reach its primary completion in 2028-02-09. Interventions recorded: Tagraxofusp, Venetoclax and Azacitidine.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06456463","url":"https://clinicaltrials.gov/study/NCT06456463"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","aml-older-unfit"],"sections":[],"technologies":["bcl2-inhibitors","cytotoxic-chemotherapy","epigenetic-drugs","kinase-inhibitors","monoclonal-antibody"],"targets":[],"drugs":["tagraxofusp","venetoclax","azacitidine"],"companies":["menarini"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06456463","phase":"2","setting":"A Phase II Multicenter Open-label Trial of Tagraxofusp (Tag) in Combination With Venetoclax and Azacitidine (Ven/Aza) in Adults With Previously Untreated CD123+ Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy","sponsor":"Stemline Therapeutics, Inc.","started":"2025-01-14","startedType":"actual","enrolled":85,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06456463/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"aml-older-unfit","kind":"cancer","name":"Acute myeloid leukaemia in older or unfit patients","route":"/cancers/aml-older-unfit/"}],"technology":[{"id":"bcl2-inhibitors","kind":"technology","name":"BCL-2 inhibitors","route":"/technologies/bcl2-inhibitors/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"},{"id":"tagraxofusp","kind":"drug","name":"Tagraxofusp","route":"/drugs/tagraxofusp/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"company":[{"id":"menarini","kind":"company","name":"Menarini / Stemline","route":"/companies/menarini/"}]}}